CS197312B2 - Method of producing 3,4-dimethoxy-6-/4-/2-furoyl/-1-piperazinyl-thiocarbamido/benzonitrile - Google Patents
Method of producing 3,4-dimethoxy-6-/4-/2-furoyl/-1-piperazinyl-thiocarbamido/benzonitrile Download PDFInfo
- Publication number
- CS197312B2 CS197312B2 CS778433A CS843377A CS197312B2 CS 197312 B2 CS197312 B2 CS 197312B2 CS 778433 A CS778433 A CS 778433A CS 843377 A CS843377 A CS 843377A CS 197312 B2 CS197312 B2 CS 197312B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- dimethoxy
- furoyl
- formula
- piperazinyl
- reacted
- Prior art date
Links
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims description 12
- SADPINFEWFPMEA-UHFFFAOYSA-N furan-2-yl(piperazin-1-yl)methanone Chemical compound C=1C=COC=1C(=O)N1CCNCC1 SADPINFEWFPMEA-UHFFFAOYSA-N 0.000 claims abstract description 9
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960001289 prazosin Drugs 0.000 claims abstract description 7
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 claims abstract description 7
- BJAYMNUBIULRMF-UHFFFAOYSA-N 2-amino-4,5-dimethoxybenzonitrile Chemical compound COC1=CC(N)=C(C#N)C=C1OC BJAYMNUBIULRMF-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- SEUMXCKRKZIQAB-UHFFFAOYSA-N 4-(furan-2-carbonyl)piperazine-1-carbothioyl chloride Chemical compound C1CN(C(=S)Cl)CCN1C(=O)C1=CC=CO1 SEUMXCKRKZIQAB-UHFFFAOYSA-N 0.000 claims abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- -1 2-furoyl Chemical group 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- 239000012442 inert solvent Substances 0.000 claims description 6
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 4
- 150000003512 tertiary amines Chemical class 0.000 claims description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 2
- HLCPWBZNUKCSBN-UHFFFAOYSA-N 2-aminobenzonitrile Chemical compound NC1=CC=CC=C1C#N HLCPWBZNUKCSBN-UHFFFAOYSA-N 0.000 claims 1
- AFGXCIJBGLMDKI-UHFFFAOYSA-N 2-isothiocyanato-4,5-dimethoxybenzonitrile Chemical compound COC1=CC(N=C=S)=C(C#N)C=C1OC AFGXCIJBGLMDKI-UHFFFAOYSA-N 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 230000003276 anti-hypertensive effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
- GDHYPPBFBJXNRE-UHFFFAOYSA-N 2-isothiocyanatobenzonitrile Chemical compound S=C=NC1=CC=CC=C1C#N GDHYPPBFBJXNRE-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Vynález se týká způsobu .výroby 3,4-dimethoxy-6- [ 4- (2-f luroyl) -1-piperazinylthiokarbamido] benzonitrilu níže uvedeného vzorce II, který je meziproduktem pro výrobu 6,7-dimethoxa-4-nmino-2- [ 4- (2-furoyl) -1píperazinyljchinazolinu (prazosinu) vzorce I,The present invention relates to a process for the preparation of 3,4-dimethoxy-6- [4- (2-fluoroyl) -1-piperazinylthiocarbamido] benzonitrile of formula II below, which is an intermediate for the preparation of 6,7-dimethoxa-4-nmino-2. - [4- (2-furoyl) -1-piperazinyl] quinazoline (prazosine) of formula I,
který je znám· jako, látka se silným antihypertensivním účinkem [Cohen, Journal of Clinical Pharmacology, 10 (1970)].which is known to be a potent antihypertensive agent [Cohen, Journal of Clinical Pharmacology, 10 (1970)].
Prazosin a •sloučeniny této skupiny se dají přpravovat několika známými způsoby, které jsou popsány v USA patentu 3 511 836, v holandském patentu 7 206 067 a v NSR patentu 2 457 911. Všechny tyto popsané způsoby mají společné to, že . se chinazolinový kruh vytvoří reakcí mezi dvěma · různými molekulami.Prazosin and compounds of this group can be prepared by several well-known methods as described in U.S. Patent 3,511,836, Dutch Patent 7,206,067, and Germany Patent 2,457,911. the quinazoline ring is formed by reaction between two different molecules.
Předmětem vynálezu je způsob výroby 3,4-dimethoxh-6- [ 4- (2-furoyl) -^рфет^^thiokarbamido] benzonitrilu vzorce II, který je novým meziproduktem pro. výrobu prazosinu, vyznačující · se tím, . že se při jeho použití chinazolinový kruh zmíněného konečného produktu vytvoří intramalekulárně. Uvedený způsob je odlišný od dříve popsaných metod.The present invention provides a process for the preparation of 3,4-dimethoxh-6- [4- (2-furoyl) -4-methoxy-thiocarbamido] benzonitrile of formula II, which is a novel intermediate for. prazosin production, characterized in that:. The method according to claim 1, wherein the quinazoline ring of said end product is formed intramalecularly. Said method is different from the previously described methods.
Nový . meziprodukt vzorce II, 3,4-dimethoxh-6-(4-( 2-furoyl) -1-piperazinylthiokarba- ;New. intermediate of formula II, 3,4-dimethoxh-6- (4- (2-furoyl) -1-piperazinylthiocarbba-;
mi6o]-bdnzoniiril, se dá převést na prazosin vzorce· I tím způsobem, že se uvede do reakce s · methyliodidem·, a vzniklý methyl-N-^á6imdthoxh-6-kyanof eDy!)- [ 4- (2-f uroyl )· -1pipdrazinyljihioformamidát vzorce IIImi6o] -bdzoniiril, can be converted to prazosin of formula (I) by reacting with methylliodide, and the resulting methyl-N- (6-dimethoxh-6-cyanophenyl) - [4- (2-uroyl) -1-piperidinyl-iodoformamidate of formula III
se cyklisuje zahříváním s amoniakem v polárním rozpouštědle a v přítomnosti amidu alkalického kovu.is cyclized by heating with ammonia in a polar solvent and in the presence of an alkali metal amide.
Za použití sloučeniny vzorce II jako výchozí látky se dá prazosin vyrábět rovněž kontinuálním způsobem, ve stále stejném rozpouštědle a bez isolace dalších meziproduktů, což značně zjednodušuje výrobu.Using the compound of formula II as a starting material, prazosin can also be prepared in a continuous manner, in the same solvent and without isolation of other intermediates, which greatly simplifies production.
Podle vynálezu se 3,4-dimethoxy-6-[4-(2f uroyl) -l-piperazinylthiokarbamido ] benzonitril vzorce II vyrábí tím způsobem, že se uvedou do reakce 3,4-dimethoxy-6-aminobenzonitril vzorce IV,According to the invention, 3,4-dimethoxy-6- [4- (2-uroyl) -1-piperazinylthiocarbamido] benzonitrile of formula II is produced by reacting 3,4-dimethoxy-6-aminobenzonitrile of formula IV,
CW3OCW 3 O
CW3OCW 3 O
thiofosgen a 1- (2-furoyl Jpiperazin vzorce VI,thiophosgene and 1- (2-furoyl) piperazine of formula VI,
Způsob podle vynálezu může být prove. den dvěma alternativními způsoby. Při prvé alternativě se uvede do reakce 3,4-dimethoxy-6-aminobenzonitril s fosgenem v inertním rozpouštědle, jako je 1,2-dichlorethan, při teplotě 0 až 20 °C v přítomnosti uhličitanu vápenatého a vzniklý 3,4-dimethoxy-6-isothiokyanatobenzonitřil vzorce VThe process of the invention may be carried out. day in two alternative ways. In a first alternative, 3,4-dimethoxy-6-aminobenzonitrile is reacted with phosgene in an inert solvent such as 1,2-dichloroethane at 0 to 20 ° C in the presence of calcium carbonate to form the 3,4-dimethoxy-6. isothiocyanatobenzonitrile of formula V
ÍVJ se nechá reagovat s l-(2-furoyl)piperazinem v inertním rozpouštědle, jako je ethylacetát, při teplotě 0 až 20 °C.The IV is reacted with 1- (2-furoyl) piperazine in an inert solvent such as ethyl acetate at a temperature of 0 to 20 ° C.
Při druhé alternativě se uvede do reakce thiofosgen a l-(2-furoyl Jpiperazin v inertním rozpouštědle, jako je dichlorethan, při teplotě 0 až 20 °C v přítomnosti terciárního aminu, jako , je triethylamin, a vzniklý 4-(2-furoyl lpiperazinylthiokarbonylchlorid vzorce VIIIn a second alternative, thiophosgene and 1- (2-furoyl) piperazine in an inert solvent such as dichloroethane are reacted at 0 to 20 ° C in the presence of a tertiary amine such as triethylamine and the resulting 4- (2-furoyl 1-piperazinylthiocarbonyl chloride) of formula VII
benzonitrilem v témže rozpouštědle při teplotě 0 až 20 °C v přítomnosti terciárního aminu.benzonitrile in the same solvent at 0 to 20 ° C in the presence of a tertiary amine.
Způsob podle vynálezu je blíže objasněn v následujících příkladech provedení.The process according to the invention is explained in more detail in the following examples.
Příklad 1Example 1
a)and)
3,4-Dimethoxy-6-isothiokyanatobenzonitril (V)3,4-Dimethoxy-6-isothiocyanatobenzonitrile (V)
Roztok 27,0 g (0,15 mol) 3,4-dimethoxy-6aminobenzonitrilu (IV) ve 150 ml 1,2-dichlorethanu se postupně, při teplotě 0 až 5°C, přidá ke směsi složené z 23,0 g (0,2 mol) thiofosgenu, 100 ml 1,2-dichlorethanu, 20,0 g (0,2 mol) uhličitanu vápenatého a 200 mililitrů vody a suspense se míchá 1 hodinu při 0 až 5QC, pak 16 hodin při 20 °C a posléze 1 hodinu při 35 °C. Reakční směs se zfil,truje, dichlorethanová vrstva se oddělí, promyje zředěnou kyselinou chlorovodíkovou a vodou a vysuší bezvodým síranem hořečnatým. Rozpouštědlo se oddestiluje za sníženého tlaku a krystalický odparek (t. t. 126 až 127 °C) se použije jako takový v následujícím stupni. Získá se 31,0 g (výtěžek 94 % teorie 3,4-dimethoxy-6-isothiokyanatobenzonitrilu.A solution of 27.0 g (0.15 mol) of 3,4-dimethoxy-6-aminobenzonitrile (IV) in 150 ml of 1,2-dichloroethane is gradually added, at 0-5 ° C, to a mixture of 23.0 g ( 0.2 moles) of thiophosgene, 100 ml of 1,2-dichloroethane, 20.0 g (0.2 mol) of calcium carbonate and 200 ml of water and the suspension was stirred for 1 hour at 0 to 5 Q C, then 16 hours at 20 ° C and then 1 hour at 35 ° C. The reaction mixture was filtered, filtered, the dichloroethane layer was separated, washed with dilute hydrochloric acid and water, and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and the crystalline residue (mp 126-127 ° C) was used as such in the next step. 31.0 g (94% of theory of 3,4-dimethoxy-6-isothiocyanatobenzonitrile) are obtained.
Pro C10H8N2O2S vypočteno:For C10H8N2O2S calculated:
54,53 % C, 3,66 % H, 12,72 % N, 14,56 % S, nalezeno:% C, 54.53;% H, 3.66;% N, 12.72;
53,43 % S, 3,78 % H, 12,18 % N, 13,79 % S.S 53.43, H 3.78, N 12.18, S 13.79.
b)(b)
3,4-Dimethoxy-6- [ 4- (2-f uroyl) -1-piperazinylthiokarbamido ] benzonitril (II)3,4-Dimethoxy-6- [4- (2-fluoroyl) -1-piperazinylthiocarbamido] benzonitrile (II)
Roztok 11,2 g (0,051 mol) 3,4-dimethoxy-6-isothiokyanobenzonitrilu (V) v 65 ml ethylacetátu se postupně přidá, za míchání a chlazení na 0°C, к roztoku 9,2 g (0,051 mol) l-(2-furoyl)piperazinu v 65 ml ethylacetátu; Roztok se nechá stát přes noc při —25 °C, vykrystalisovaný produkt se odfiltruje, promyje studeným ethylacetátem a vysuší. Získá se 16,3 g (výtěžek 80 % teorie) 3,4-dimethoxy-6- [ 4- (2-f uroyl) -l-piperazinylthiokarbamido jbenzonitrllu o teplotě tání 178 až 180 stupňů Celsia.A solution of 11.2 g (0.051 mol) of 3,4-dimethoxy-6-isothiocyanobenzonitrile (V) in 65 ml of ethyl acetate is gradually added, with stirring and cooling to 0 ° C, to a solution of 9.2 g (0.051 mol) of 1- (2-furoyl) piperazine in 65 mL ethyl acetate; The solution was allowed to stand overnight at -25 ° C, the crystallized product was filtered off, washed with cold ethyl acetate and dried. 16.3 g (80% of theory) of 3,4-dimethoxy-6- [4- (2-fluoroyl) -1-piperazinylthiocarbamido] benzonitrile, m.p. 178 DEG-180 DEG C., are obtained.
Pro C19H20N4O4S vypočteno:Calcd for C19H20N4O4S:
56,99 % C, 5,03 % H, 13,99 % N,% C, 56.99;% H, 5.03;% N, 13.99.
8,01 % s, se nechá reagovat s 3,4-dimethoxy-6-amino1973128.01% s, was reacted with 3,4-dimethoxy-6-amino197312
В naiezepo: 'В naiezepo: '
57,41 % C, .5,39 % H, 14,14 % N, 7,68 % S.% C, 57.41;% H, 5.39;% N, 14.14;
P ř í k l'a d 2Example 2
3,4-Dimethoxy-6- [ 4- (2-f uroyl-1-piperaziny lihiokarbamido ] benzoniir il (II)3,4-Dimethoxy-6- [4- (2-fluoroyl-1-piperazinyl-liocarbamido) -benzonitrile (II)
5,0 g (0,028 mol) l-(l-f uroyl )piperazinu (VI) a 2,83 g (0,028 mol) triethylaminu se rozpusií v 60 ml. dichlormethanu a roziok se přidá, za míchání a chlazení na teplotu asi 0 °C, ke směsi 3,86 g (0,0336 mol) ihiofosgenu s 50 ml dichlormethanu. Reakční směs se míchá 2 hodiny při 0 °C a 3 hodiny při teplotě místnosti, vyloučený hydrochlorid irieihylaminu se odfiltruje .a z filtrátu se oddestiluje rozpouštědlo za . sníženého tlaku.. Odparek, ' 4-(2-furoyl )piperazinylthiokarbonylchlorid (VII), se rozpustí v 50 ml dichlormethanu a roztok se přidá, za míchání a chlazení na 0°C, k roztoku . 4,98 g (0,02& mol.) ' 3,4-dimetihoxy-6-aminobenzónitrilu .Dissolve 5.0 g (0.028 mol) of 1- (1-uroyl) piperazine (VI) and 2.83 g (0.028 mol) of triethylamine in 60 ml. of dichloromethane and the solution was added, with stirring and cooling to about 0 ° C, to a mixture of 3.86 g (0.0336 mol) of iophiophosgene with 50 ml of dichloromethane. The reaction mixture is stirred at 0 ° C for 2 hours and at room temperature for 3 hours, the precipitated iriehylamine hydrochloride is filtered off and the solvent is distilled off from the filtrate. The residue, 4- (2-furoyl) piperazinylthiocarbonyl chloride (VII), was dissolved in 50 ml of dichloromethane and the solution was added, with stirring and cooling to 0 ° C, to the solution. 4.98 g (0.02 < mol >) of 3,4-dimethoxy-6-aminobenzonitrile.
(IV) a 2,83 g (0,028 mol) triethylaminu v 60 mililitrech dichlormethanu. Reakční směs se míchá . 2 hodiny při 0 °C a pak 2 až 3 hodiny při teplotě místnosti,, vyloučený hydrochlorid triethylaminu se . odfiltruje, roztok se promyje ' vodou, vysuší bezvodým síranem horečnatým. .a rozpouštědlo se oddestiluje za sníženého tlaku. K odparku se přidá ethylacetát, roztok se ochladí na —25 °C a vyloučený produkt . se odfiltruje. Získá se 6,2 g (výtěžek 55 % teorie) 3,4-dimethoxy-6-[4-(2-f uroyl) -1-piperaziny lthiokarbamido) benzonitrilu o t. t. 175 až .179 °C. .(IV) and 2.83 g (0.028 mol) of triethylamine in 60 ml of dichloromethane. The reaction mixture was stirred. 2 hours at 0 ° C and then 2 to 3 hours at room temperature, the precipitated triethylamine hydrochloride was added. filtered, the solution was washed with water, dried over anhydrous magnesium sulfate. and the solvent is distilled off under reduced pressure. Ethyl acetate was added to the residue, the solution was cooled to -25 ° C and the precipitated product was collected. is filtered off. 6.2 g (yield 55% of theory) of 3,4-dimethoxy-6- [4- (2-fluoroyl) -1-piperazinylthiocarbamido) benzonitrile of m.p. 175 DEG -179 DEG C. are obtained. .
Prazosin . lze ze . sloučeniny vzorce II vyrábět . následujícím způsobem. ,Prazosin. can be from. compounds of formula II to produce. as follows. ,
Příklad. 3Example. 3
a)and)
I-Iydrojodid. methyl-N-(3,4-dimethoxy-6-]kymiofen.yl )-(4-( 2-f uroyl) -1-piperazinyl ] ihioformamidátu (III. HJ)I-Iydrojodide. Methyl N- (3,4-dimethoxy-6-] thiophenyl) - (4- (2-fluoroyl) -1-piperazinyl] iioformamidate (III. HJ)
K roztoku 20,0 g (0,05 mol) . 3,4-dimethoxy-6- [ 4- (2-f uroyl) -1-piperaziny lthiokar bainidojbenzonítrilu ve 200 ml bismethoxyethyletheru (dlglymu) se přidá 14,2 g (0,1 mol) methyljodidu a směs se zahřívá 9 hodin na 60 °C. Roztok se ochladí na . teplotu místnosti, vyloučený krystalický reakční produkt se odfiltruje, promyje etherem .a vysuší. Získá se 24,6 g (výtěžek . 90 % teorie) hydrojodidu methyl-N- (3,4-dimethoxy-6-kyanofeny 1) - [ 4- (2-f uroyl) -1-piperazinyl ] thioformamidátu o. t. t. 163 °C.To a solution of 20.0 g (0.05 mol). 3,4-dimethoxy-6- [4- (2-fluoroyl) -1-piperazinylthiocar-bainidobenzonitrile in 200 ml of bismethoxyethyl ether (dlglyme) is added 14.2 g (0.1 mol) of methyl iodide and the mixture is heated for 9 hours at room temperature. 60 ° C. The solution is cooled to. The precipitated crystalline reaction product is filtered off, washed with ether and dried. 24.6 g (yield: 90% of theory) of methyl N- (3,4-dimethoxy-6-cyanophenyl) - [4- (2-fluoroyl) -1-piperazinyl] thioformamidate, mp 163 ° C, are obtained. .
Pro .C20H23IN4O4S vypočteno:Calcd for C20H23IN4O4S:
44,29 % C, 4,27 % H, 23,39 % I,44.29% C, 4.27% H, 23.39% I,
10,33 % N, 5,91 % S, nalezeno: .N, 10.33. S, 5.91. Found:.
44,25 % . C, 4,26 % H, 22,93 % 1,.44.25%. C, 4.26; H, 22.93;
• 9,61 «/o N, 5,58 % S.9.61% N, 5.58% S.
b)(b)
Methyl-N- (3,4-cilme thoxy-6-kyanofenyl-(4-( 2-f uroyl) 1-piperazinyl ] ihioformamidát (III)Methyl N- (3,4-cilmethoxy-6-cyanophenyl- (4- (2-fluoroyl) 1-piperazinyl) ihioformamidate (III)
K roztoku hydrojódidu methyl-N- (3,4-dimethoxy-6-kyanof eny 1) - [ 4- (2-f uroyl) -1-piperazinyl] ihioformamidátu ' (62,0 g, 0,114 mol) ve 350 ml . methanolu se za míchání, při 0 až 5 °C, přidá. ' 186 ml 25% vodného amoniaku. Směs se míchá 2 hodiny při 0 °C, pak se vyloučená látka odfiltruje a promyje etherem. Získá se . 42,7 g'(výtěžek 90% . teorie) methyl-N- (3,4 - dime thoxy-6-k у anofeny 1) - ( 4-.(2-furcyi) -1-plperazinyl ] thioformainidátu· o 1.1. 105 až 107 °C.To a solution of methyl N- (3,4-dimethoxy-6-cyanophenyl) - [4- (2-fluoroyl) -1-piperazinyl] -isoformoformamide hydroiodide (62.0 g, 0.114 mol) in 350 mL. of methanol is added with stirring at 0 to 5 ° C. 186 ml of 25% aqueous ammonia. The mixture was stirred at 0 ° C for 2 hours, then the precipitate was filtered off and washed with ether. It is obtained. 42.7 g (yield 90% of theory) of methyl N- (3,4-dimethoxy-6-quinophenyl) - (4- (2-furcyl) -1-plperazinyl) thioformainidate o 1.1 105-107 ° C.
Pro C20H22N4O4S .For C 20 H 22 N 4 O 4 S.
vypočteno:calculated:
57,96 % C, 5,36 % H, 13,52 % . N, 7,73 % S, nalezeno:C 57.96, H 5.36, 13.52%. N, 7.73% S, found:
58,01 % C, 5,54 % . H, 13,73 % N, 7,53 % S.58.01% C, 5.54%. H, 13.73; N, 7.53.
c) .c).
6,--Dimothoxa-4-nmino-2- [ 4- (2-f uroyl) -1-piperazinyl Jchinazolín (I) >6, - Dimothoxa-4-amino-2- [4- (2-fluoroyl) -1-piperazinyl] quinazoline (I)>
K roztoku 7,0 g (0,017 mol) . methyl-N-(3,4dimethoxy-6-kyanof enyl )-(4-( 2-f uroyl) -1-piperazinylj ihioformamidátu ve 100 ml formamiďu . se přidá 2,0 g (0,051 mol) . amidu sodného. Roztok se nasytí při 0 QC plynným amoniakem, pak se teplota směsi . postupně zvýší na 120 °C . a na iéio teplotě se . udržuje po dobu 24 hodin . za uvádění plynného . amoniaku. Po ochlazení se reakční směs nalije do 100 ml ledové vody a směs se extrahuje O—^rai . vždy po 50 ml chloroformu. Chloroformové extrakty se spojí, promyjí 4 X 50 ml vody, vysuší a rozpouštědlo se oddestiluje . za sníženého . tlaku. Odparek se překrysialisuje ze směsi ethanolu s vodou (50:15); získá se 6,--dtmethoxymiamino-2- [ 4- (2-f uroyl) -1-piperazinyl ]chlnazolin o t. t. . 262 až 264 °C. Infračervené . a nukleární magnetické rezonanční spektrum získaného produktu bylo ideniické s analogickými . spektry sloučenin připravené způsobem popsaným v literatuře.To a solution of 7.0 g (0.017 mol). methyl N- (3,4-dimethoxy-6-cyanophenyl) - (4- (2-fluoroyl) -1-piperazinyl) ioformoformamidate in 100 ml of formamide was added 2.0 g (0.051 mol) of sodium amide. saturated at 0 Q C with ammonia gas, then the temperature of the mixture. progressively increased to 120 ° C. and ieio temperature. maintained for 24 hrs. for placing the gas. ammonia. after cooling, the reaction mixture was poured into 100 ml of ice water and The mixture was extracted with chloroform (50 ml) and the combined chloroform extracts were washed with water (4.times.50 ml), dried and the solvent was distilled off under reduced pressure, and the residue was recrystallized from ethanol / water (50:15). There was obtained 6, 6-dimethoxymiamino-2- [4- (2-fluoroyl) -1-piperazinyl] -chlorosoline, mp 262-264 [deg.] C. The infrared and nuclear magnetic resonance spectra of the product obtained were identical with analogous spectra. compounds prepared as described in the literature.
Pro C19H21N5O4 vypočteno: 'For C19H21N5O4 calculated:
59,52 % . C, 5,52 % . H, 18,27 % N, nalezeno:59.52%. C, 5.52%. H, 18.27% N, found:
59,28 % С, 5,88 % Η, 17,99 % Ν.59.28% С, 5.88% Η, 17.99% Ν.
Ρ ř ί к 1 a d 4К к 1 and d 4
6,7-Dime thoxy-4-amino-2- [ 4- (2-f uroyl) -1-piperazinyl ] -chínazolin (I)6,7-Dimethoxy-4-amino-2- [4- (2-fluoroyl) -1-piperazinyl] quinazoline (I)
17,6 (0,044 mol] 3,4-dimethoxy-6-[4-(2-furoyl) -1-piperazinylthiokarbamido] benzonitrilu se rozpustí ve 100 ml formamidu, к roztoku se přidá 12,5 g (0,088 mol) methyljodidu a směs se zahřívá 9 hodin na 60 °C. Přebytek methyljodidu se oddestiluje, roztok se nasytí při Q°C plynným amoniakem a ks směsi se přidá 6,9 g (0,176 mol) amidu sodného. Teplota reakční směsi se zvýší na 120 až 140 °C a na této teplotě se udržuje po dobu 24 hodin za uvádění plynného amoniaku. Po ochlazení se roztok nalije do ledové vody (150 ml) a produkt se vyextrahuje do chloroformu (8X 50 ml). Spojené chloroformové extrakty se promyjí vodou, odbarví aktivním uhlím, vysuší a rozpouštědlo se oddestiluje za sníženého tlaku. Odparek poskytne po překrystalisování ze směsi ethanolu s vodou (50:15) 6,7-dimethoxy-4-amino-2-[4-(2-furoyl)-l-píperazinyl)chlnazolin o t. t. 263 až 265 °C.17.6 (0.044 mol) 3,4-dimethoxy-6- [4- (2-furoyl) -1-piperazinylthiocarbamido] benzonitrile is dissolved in 100 ml of formamide, 12.5 g (0.088 mol) of methyl iodide are added to the solution, and The mixture was heated at 60 DEG C. for 9 hours, excess methyl iodide was distilled off, the solution was saturated at 0 DEG C. with ammonia gas, and 6.9 g (0.176 mol) of sodium amide was added to the mixture. The solution was poured into ice water (150 ml) and the product was extracted into chloroform (8X50 ml) .The combined chloroform extracts were washed with water, decolourised with charcoal. The residue was recrystallized from ethanol / water (50:15) to give 6,7-dimethoxy-4-amino-2- [4- (2-furoyl) -1-piperazinyl] chlorazoline. mp 263-265 ° C.
Claims (2)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI763614A FI58124C (en) | 1976-12-15 | 1976-12-15 | NY MELLANPROTUKT 3,4-DIMETOXY-6- (4- (2-FUROYL) -1-PIPERAZINYLTHOUREA) -BENONITRIL FOR FRAMSTAELLNING AV 6,7-DIMETOXY-4-AMINO-2- (4- (2-FUROYL) -1 -PIPERAZINYL) QUINAZOLINE WITH BLODTRYCKSSAENKANDE VERKAN |
Publications (1)
Publication Number | Publication Date |
---|---|
CS197312B2 true CS197312B2 (en) | 1980-04-30 |
Family
ID=8510504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CS778433A CS197312B2 (en) | 1976-12-15 | 1977-12-15 | Method of producing 3,4-dimethoxy-6-/4-/2-furoyl/-1-piperazinyl-thiocarbamido/benzonitrile |
Country Status (17)
Country | Link |
---|---|
JP (1) | JPS5387375A (en) |
AT (1) | AT358047B (en) |
BE (1) | BE861822A (en) |
CA (1) | CA1102332A (en) |
CH (1) | CH630624A5 (en) |
CS (1) | CS197312B2 (en) |
DD (1) | DD134226A1 (en) |
DE (1) | DE2755638A1 (en) |
DK (1) | DK145822C (en) |
FI (1) | FI58124C (en) |
HU (1) | HU174048B (en) |
NL (1) | NL7713703A (en) |
NO (1) | NO146239C (en) |
PL (1) | PL106201B1 (en) |
SE (1) | SE424993B (en) |
SU (1) | SU923370A3 (en) |
ZA (1) | ZA777222B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI67699C (en) * | 1979-01-31 | 1985-05-10 | Orion Yhtymae Oy | PROCEDURE FOR THE FRAMSTATION OF AV 6,7-DIMETOXY-4-AMINO-2- (4- (2-FUROYL) -1-PIPERAZINYL) QUINAZOLINE HYDROCHLORIDE WITH BLODTRYCKSSAENKANDE VERKAN |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3935213A (en) * | 1973-12-05 | 1976-01-27 | Pfizer Inc. | Process for hypotensive 4-amino-2-(piperazin-1-yl) quinazoline derivatives |
-
1976
- 1976-12-15 FI FI763614A patent/FI58124C/en not_active IP Right Cessation
-
1977
- 1977-11-24 CH CH1438277A patent/CH630624A5/en not_active IP Right Cessation
- 1977-11-25 SE SE7713377A patent/SE424993B/en not_active IP Right Cessation
- 1977-12-05 ZA ZA00777222A patent/ZA777222B/en unknown
- 1977-12-05 AT AT867177A patent/AT358047B/en not_active IP Right Cessation
- 1977-12-11 NL NL7713703A patent/NL7713703A/en not_active Application Discontinuation
- 1977-12-12 NO NO774263A patent/NO146239C/en unknown
- 1977-12-13 HU HU77OI217A patent/HU174048B/en not_active IP Right Cessation
- 1977-12-13 PL PL1977202898A patent/PL106201B1/en unknown
- 1977-12-14 BE BE183425A patent/BE861822A/en not_active IP Right Cessation
- 1977-12-14 DE DE19772755638 patent/DE2755638A1/en not_active Ceased
- 1977-12-14 SU SU772555751A patent/SU923370A3/en active
- 1977-12-14 DK DK558377A patent/DK145822C/en not_active IP Right Cessation
- 1977-12-14 CA CA293,066A patent/CA1102332A/en not_active Expired
- 1977-12-15 JP JP15157177A patent/JPS5387375A/en active Granted
- 1977-12-15 CS CS778433A patent/CS197312B2/en unknown
- 1977-12-15 DD DD77202667A patent/DD134226A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
DK145822C (en) | 1983-08-29 |
SU923370A3 (en) | 1982-04-23 |
BE861822A (en) | 1978-03-31 |
DE2755638A1 (en) | 1978-06-22 |
DK145822B (en) | 1983-03-14 |
NO146239C (en) | 1982-08-25 |
PL202898A1 (en) | 1978-08-28 |
FI763614A7 (en) | 1978-06-16 |
CA1102332A (en) | 1981-06-02 |
ZA777222B (en) | 1978-09-27 |
AT358047B (en) | 1980-08-11 |
DK558377A (en) | 1978-06-16 |
FI58124C (en) | 1980-12-10 |
JPS5387375A (en) | 1978-08-01 |
ATA867177A (en) | 1980-01-15 |
PL106201B1 (en) | 1979-12-31 |
HU174048B (en) | 1979-10-28 |
NL7713703A (en) | 1978-06-19 |
DD134226A1 (en) | 1979-02-14 |
SE424993B (en) | 1982-08-23 |
SE7713377L (en) | 1978-06-16 |
NO774263L (en) | 1978-06-16 |
FI58124B (en) | 1980-08-29 |
NO146239B (en) | 1982-05-18 |
JPS6225145B2 (en) | 1987-06-01 |
CH630624A5 (en) | 1982-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2094428C1 (en) | Method of synthesis of benzopyrane compounds, intermediate compounds and methods of their synthesis | |
HU195182B (en) | Process for production of /z/-1-phenil-1-diethil-amino-carbonil-2-amino-methil-cyclopropan hcl | |
KR100490220B1 (en) | Process for the preparation of 4-oxoimidazolinium salts | |
FI91064C (en) | Process for the preparation of therapeutically active 3- (N-acylethylaminoalkyl) chromanes and -1,4-dioxanes | |
US4308206A (en) | Process for preparing derivatives of 5,11-dihydro-6h-pyrido[2,3-b][1,4]-benzodiazepin-6-one, and the final derivatives and synthesis intermediates obtained thereby | |
CS197312B2 (en) | Method of producing 3,4-dimethoxy-6-/4-/2-furoyl/-1-piperazinyl-thiocarbamido/benzonitrile | |
US9359333B2 (en) | Efficient process for the preparation of Lapatinib and salts thereof by means of new intermediates | |
JP2001064282A (en) | Imidazoline compound, its intermediate and production thereof and production of azepine compound and its salt | |
US4575553A (en) | Antitumor m-AMSA analog | |
RU1838309C (en) | Method of synthesis of quinazoline derivatives or their pharmaceutically acceptable acid-additive salts | |
US4927970A (en) | Substituted 3-cyclobutene-1,2-dione intermediates | |
JPS6355512B2 (en) | ||
HU200996B (en) | Process for producing n-(3', 4'-dimethoxycinnamoyl)-anthranilic acid (tranilast) | |
KR20040043176A (en) | Process for the preparation of 5-substituted isobenzofurans | |
FI88292B (en) | FRAME STARTING FOR N- (SULPHONYLMETHYL) FORMAMIDER | |
CS195347B2 (en) | Process for preparing antihypertensive 6,7-dimethoxy4-4-amino-2-/4-/2-furoyl/-1-piperazinyl/quinazoline | |
KR101170024B1 (en) | Preparation method of azosemide | |
RU2744470C1 (en) | Method for producing isothiobarbamine | |
KR20190131983A (en) | Novel processes for preparing a diaminopyrimidine derivative or acid addition salt thereof | |
US5151544A (en) | Intermediates in the preparation of chiral spirofluorenehydantoins | |
PL152958B1 (en) | Method for manufacturing piperazine derivatives | |
SU437294A1 (en) | The method of obtaining derivatives of 2-amino-dihydro-benzodiazepinone | |
SU416944A3 (en) | METHOD OF OBTAINING DERIVATIVES | |
JPH0386869A (en) | Production of quinazoline derivative | |
JPH0227346B2 (en) |